AI sensors are replacing needles in cardiovascular care
This article is a part of Startup Spotlight, a series that features young, up-and-coming startups.
This article is brought to you in collaboration with the Slingshot deep tech startup competition, held at the Singapore Week of Technology and Innovation.

Kasper Bourdette , Co-founder and CEO (left), Jakob Gelberg, CTO (middle), and Filip Peters, Co-founder and CEO (right)/ Photo credit: Acorai
Heart failure management often relies on invasive procedures to measure internal pressures. Patients endure discomfort, while hospitals face inefficient assessment workflows. Acorai aims to address this clinical gap by digitizing and simplifying cardiovascular monitoring.
😟 Problem
Over 60 million people globally live with heart failure. Doctors often lack reliable, non-invasive tools to accurately assess patients’ conditions. This gap contributes to unnecessary hospital admissions and prolonged stays.
These inefficiencies account for an estimated US$8.9 billion in avoidable hospital costs annually. Emergency departments and cardiology units face significant pressure when managing suspected or confirmed heart failure cases.
💡 Solution
The startup developed a portable device that estimates pressures inside the heart and lungs without needles. Its technology combines advanced sensors and AI to deliver results quickly.
The system offers several clinical capabilities:
- Provides non-invasive pressure readings in under five minutes.
- Assists doctors in making hospital admission and discharge decisions.
- Guides ongoing treatment for patients in heart failure clinics.

Image credit: Acorai
📊 Market size
The startup operates within a growing sector for specialized cardiovascular care. It specifically targets a global market valued at over US$3 billion. Providers increasingly demand faster and more affordable monitoring solutions.
🤝 Team
- Filip Peters. Co-founder and CEO. He brings experience in machine learning and quantitative finance, as well as an MA in Economics from the University of Edinburgh.
- Kasper Bourdette. Co-founder and COO. He has a background in management consulting, including strategy projects across several industries, and previously worked as an associate principal at Ericsson.
- Jakob Gelberg. CTO. He previously worked in the technology, renewable energy, and climate tech industries.
🚀 Traction
- Tested its technology in more than 2,000 patients.
- Completed a 1,600-patient clinical study across 20 hospitals.
- Received FDA Breakthrough Device Designation in 2023.
- Secured a S$1 million (US$775,194) paid pilot program with SingHealth and NHG Health in Singapore.
- Established international hospital partnerships across the US, Europe, and Asia.







